Skip to main content
. 2013 Jun 4;21(9):1749–1757. doi: 10.1038/mt.2013.112

Figure 4.

Figure 4

Sunitinib enhances the oncolytic efficacy of VSV against PC3 prostate tumors in nude mice. Oral gavage with sunitinib began on day 16 postimplantation of PC3 cells. Intratumoral injections of VSV were done on days 19 and 36 (arrows) and day 41 (in upper plot) postimplantation. Tumor sizes were measured using a digital caliper and data were analyzed in GraphPadPrizm. Su, sunitinib; VSV, vesicular stomatitis virus.